Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability and pharmacology of ENB-0040 in infantile hypophosphatasia
2008-007406-11Phase 2Completed
- Sponsor
- Enobia Pharmaceuticals
- Start
- Jan 2009
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asfotase alfa in infantile hypophosphatasia (HPP), sponsored by Enobia Pharmaceuticals. Primary endpoint: Radiographic skeletal changes. Started Jan 2009; status: completed.
02
Drugs
asfotase alfa
03
Conditions
infantile hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2008-007406-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007406-11.